SCHEMBL1703532

SCHEMBL1703532

CC(c1nc2ccsc2c(=O)n1-c1ccccc1)n1cnc2c(N)cccc21

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 13/20 0.69
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
PIK3R1 P27986 5/20 0.40
POLB P06746 2/20 0.38
TSHR P16473 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10330136 0.86 PIK3CD (0.77) PIK3CDALDH1A1SMN1; SMN2MEN1GAA
SCHEMBL937877 0.82 PIK3CD (0.68) PIK3CDMEN1KMT2APIK3R1PDE4A
SCHEMBL360489 0.82 PIK3CD (1.00) PIK3CDALDH1A1SMN1; SMN2PIK3R1
SCHEMBL1703459 0.77 ALDH1A1 (0.61) PIK3CDALDH1A1SMN1; SMN2MEN1GAA
SCHEMBL1755796 0.76 ALDH1A1 (0.64) PIK3CDALDH1A1SMN1; SMN2MEN1GAA
SCHEMBL1703480 0.74 ALDH1A1 (0.61) PIK3CDALDH1A1SMN1; SMN2MEN1GAA
SCHEMBL12912405 0.72 PIK3CD (0.58) PIK3CDPIK3R1PDE4APDE4BPDE4C
SCHEMBL1703546 0.71 ALDH1A1 (0.57) PIK3CDALDH1A1SMN1; SMN2MEN1GAA
SCHEMBL1703341 0.71 ALDH1A1 (0.57) PIK3CDALDH1A1SMN1; SMN2MEN1GAA
SCHEMBL12912425 0.69 PIK3CD (0.75) PIK3CDPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216820-A1 THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS ICOS CORPORATION 2010-08-26 US claimed
EP-2441768-A1 Thienopyrimidinones for treatment of inflammatory disorders and cancers Eli Lilly & Co. (US) 2012-04-18 EP disclosed
US-20100216820-A1 THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS ICOS CORPORATION 2010-08-26 US disclosed
US-20100216820-A1 THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS ICOS CORPORATION 2010-08-26 US disclosed
US-20100216820-A1 THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS ICOS CORPORATION 2010-08-26 US disclosed
CN-101605797-A The Thienopyrimidinones of treatment inflammatory disease and cancer LILLY CO ELI (US) 2009-12-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216820-A1 THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS PIK3CA, PIK3CD, PIK3CB PIK3CD 2/4885ALDH1A1 1821/4885SMN1; SMN2 3934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.